Qlik today announced a new partnership with ServiceNow designed to help enterprises bring trusted enterprise context and richer insight into the workflows and AI-driven processes where decisions turn ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Benchmark started coverage of ServiceNow (NOW) with a Buy rating and a $125 price target. Shares of ServiceNow were largely flat on Wednesday. "We are initiating coverage of ServiceNow, Inc. (NOW) ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The proliferation of artificial intelligence tools could push unemployment among college grads into the mid-30s, according to ServiceNow CEO Bill McDermott. Businesses are slashing costs, cutting jobs ...

Sheryl Underwood opened up a bit about her feud with Sharon Osbourne and her time on “The Talk” while guest hosting “The View” on Tuesday. But, when Joy Behar poked a little fun at her for everything ...

It seems that most universities began taking up the topic of artificial intelligence in a transactional way following the release of ChatGPT’s general release at the end of 2022. First, it was student ...

This week, “The View” has been feeling different from how it has in years. Suddenly, it’s relevant. One might think this is nothing new — after all, in the first Trump presidency, and before that for ...

Fears of AI displacing software companies resulted in share price drops for ServiceNow and Salesforce. Salesforce saw 9% year-over-year revenue growth in the third quarter and raised its 2025 ...

Microsoft Sentinel data lake tier now supports Advanced Hunting Tables ingestion for lower-cost security storage. Defender telemetry flows directly into Sentinel data lake, enabling extended retention ...

FDA clearance advances phase 2b evaluation of teverelix in advanced prostate cancer patients where ADT choice is constrained by high baseline cardiovascular risk. Trial design targets rapid, durable ...